Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: A report of two instructive cases.

about

Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: A report of two instructive cases.

Item

http://www.wikidata.org/entity/Q50037194

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Molecular characterization of ...... port of two instructive cases.

@en

Molecular characterization of ...... port of two instructive cases.

@nl

type

Item

label

Molecular characterization of ...... port of two instructive cases.

@en

Molecular characterization of ...... port of two instructive cases.

@nl

prefLabel

Molecular characterization of ...... port of two instructive cases.

@en

Molecular characterization of ...... port of two instructive cases.

@nl

P1476

Molecular characterization of ...... port of two instructive cases.

@en

P2093

Christopher S Hughes

http://www.w3.org/2001/XMLSchema#string

Daniel J Renouf

http://www.w3.org/2001/XMLSchema#string

Daniel R Owen

http://www.w3.org/2001/XMLSchema#string

David F Schaeffer

http://www.w3.org/2001/XMLSchema#string

Gregg B Morin

http://www.w3.org/2001/XMLSchema#string

Howard Lim

http://www.w3.org/2001/XMLSchema#string

Hui-Li Wong

http://www.w3.org/2001/XMLSchema#string

Janessa Laskin

http://www.w3.org/2001/XMLSchema#string

Martin Jones

http://www.w3.org/2001/XMLSchema#string

Melika Bonakdar

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

Comprehensive molecular characterization of human colon and rectal cancer

MUC1 Predicts Colorectal Cancer Metastasis: A Systematic Review and Meta-Analysis of Case Controlled Studies

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein

P31

scholarly article

P356

10.1101/MCS.A002535

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marco Marra

P577

2018-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29438965

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5880263

http://www.w3.org/2001/XMLSchema#string